Can an asthma inhaler help treat coronavirus?

Science, technology and technology news

Can an asthma inhaler help treat coronavirus?

Britain found a way to speed up the treatment of COVID-19

According to a preliminary study by scientists from the UK, the use of asthma inhalers can help patients with coronavirus – the recovery time is reduced by an average of three days. This was stated by Deputy Minister of Health Joe Churchill during a speech in the British Parliament, reports The Telegraph.

According to her, the study showed that the treatment time is shortened by inhalation of budesonide, a medicine used for asthma and chronic obstructive pulmonary disease. At the same time, Churchill stressed that the conclusions are based only on intermediate research results, and “a full analysis is currently being carried out to understand all the consequences of this treatment.”

“Clinical guidelines have been issued for physicians to prescribe inhaled budesonide on an individual basis, but inhaled budesonide is currently not recommended as the treatment standard in the UK,” the politician added.

She stressed that the recommendations would be adjusted as necessary when more detailed data became available.

Sir Graham Brady, a senior British official at COVID-19 headquarters, said that he first considered using inhalers after a therapist told him that very few coronavirus patients with asthma were admitted to hospitals.

Last month, the European Medicines Regulator (EDQM) reported that there is little evidence yet that the use of inhaled corticosteroids in COVID-19 patients alleviates and shortens the course of the disease, Reuters reports.

In April this year, the Center for Biomedical Research of the British National Institute of Medicine and the Anglo-Swedish pharmaceutical company AstraZeneca conducted an experiment in Oxfordshire on the use of inhalers for COVID-19, which was approved by the Fulham Research Ethics Committee of London and the National Office for Medical Research.

Participants in one group received budesonide, two inhalations twice a day, while other patients in the parallel group received conventional treatment for 7 days after the onset of mild symptoms of COVID-19.

As a result, the scientists concluded that the administration of inhaled budesonide reduced the likelihood of a need for urgent medical attention and shortened the recovery time from COVID-19. The research is described in the journal Lancet.

Earlier it was reported that asthmatics themselves tolerate a new type of coronavirus more easily, but not because of the use of inhalers, but because of the properties of the pathology itself, noted the head of the Department of Clinical Immunology and Allergology and the International Laboratory of Immunopathology of Sechenov University, Academician of the Russian Academy of Sciences Alexander Karaulov.

In an interview with Izvestia, he said that among comorbid patients with COVID-19, asthma is much less common than usual in the population, sometimes even twice or three times less often.

“That is, asthma may be a protective factor against coronavirus. One of the reasons for this is a special type of inflammation that all allergy sufferers have, Th-2-mediated. Perhaps it is the polarization of the immune response in this direction that protects patients with allergic asthma from severe course and death, ”the scientist said.

Leave a Reply

seven − 1 =